0. DOCID:25519 SCORE: 0.00345466236987213
DOCNO: 11394005
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Liver Transplantation
QUALIFIER: pathology
QUALIFIER: secondary
QUALIFIER: surgery
AUTHOR: K Urata K
AUTHOR: S Kawasaki S
AFFILIATION: First Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
PUBTYPE: Journal Article
JOURNALTITLE: Nippon Geka Gakkai zasshi.
COUNTRY: Japan
TITLE: [Liver transplantation for liver metastases of colorectal cancer]
PUBDATE: 20010501
Because of the critical shortage of donor organs, liver transplantation for metastatic tumors should be reserved for patients in whom long-term survival is possible. Transplantation in patients with metastatic tumors from colorectal cancer has resulted only in short disease-free intervals, and palliation was achieved in only a few patients. In patients with symptomatic neuroendocrine tumors unresponsive to conventional therapy, on the other hand, reasonably good disease-free intervals and prolonged survival may justify liver transplantation.


1. DOCID:27943 SCORE: 0.00331663026016405
DOCNO: 10559547
AUTHOR: D W Lamson DW
AUTHOR: M S Brignall MS
AFFILIATION: Tahoma Clinic, Kent, WA, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Alternative medicine review : a journal of clinical therapeutic.
COUNTRY: UNITED STATES
TITLE: Antioxidants in cancer therapy; their actions and interactions with oncologic therapies.
PUBDATE: 19991001
There is a concern that antioxidants might reduce oxidizing free radicals created by radiotherapy and some forms of chemotherapy, and thereby decrease the effectiveness of the therapy. The question has arisen whether concurrent administration of oral antioxidants is contraindicated during cancer therapeutics. Evidence reviewed here demonstrates exogenous antioxidants alone produce beneficial effects in various cancers, and except for a few specific cases, animal and human studies demonstrate no reduction of efficacy of chemotherapy or radiation when given with antioxidants. In fact, considerable data exists showing increased effectiveness of many cancer therapeutic agents, as well as a decrease in adverse effects, when given concurrently with antioxidants.


2. DOCID:27835 SCORE: 0.00282087027839273
DOCNO: 11225056
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pharmacology
QUALIFIER: adverse effects
QUALIFIER: drug effects
QUALIFIER: radiation effects
QUALIFIER: drug effects
AUTHOR: T T Puck TT
AUTHOR: R Johnson R
AUTHOR: P Webb P
AFFILIATION: Eleanor Roosevelt Institute, 1899 Gaylord Street, Denver, Colorado 80206, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Somatic cell and molecular genetics.
COUNTRY: United States
TITLE: Mutation inhibition by beta-estradiol after low doses of gamma-irradiation of mammalian cells.
PUBDATE: 19990301
The methodology previously described for measuring mutagenesis has been applied to the study of mutation prevention in immortalized G2 phase human lymphocytes exposed to 25 and 50 cGy of gamma-radiation. Caffeine prevents repair of mutations. Two times 10(-4) M beta-estradiol applied for 2.5 h markedly decreases induced mutations and affects male and female cells similarly. Quantitative measurement of mutagenesis in cells of different individuals and the effect of various agents on mutation yield should be important in prevention of cancer and other mutational disease.


3. DOCID:24955 SCORE: 0.0028155324793371
DOCNO: 9555537
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: radiotherapy
AUTHOR: H Wagner H
AFFILIATION: Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in oncology.
COUNTRY: UNITED STATES
TITLE: Enhancing the role of radiotherapy in non-small cell lung cancer.
PUBDATE: 19980301
Radiation therapy plays an important role in the treatment of patients with unresectable non-small cell lung cancer. Local control rates with past radiation therapy techniques have been poor, in the range of 10% to 15%. Recent advances in dose planning and delivery, as well as radiation biology, offer the promise of improved control and better protection of dose limiting normal tissues.


4. DOCID:24953 SCORE: 0.00281553209284645
DOCNO: 9679589
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: classification
AUTHOR: A Kaneko A
AFFILIATION: Division of Ophthalmology, National Cancer Center, Tokyo, Japan.
PUBTYPE: Journal Article
JOURNALTITLE: Gan to kagaku ryoho. Cancer & chemotherapy.
COUNTRY: JAPAN
TITLE: [TNM classification of ophthalmic malignant tumors]
PUBDATE: 19980701
The present TNM classification of ophthalmic malignant tumors (lid cancer, malignant melanoma of the lid, conjunctival cancer, conjunctival malignant melanoma, uveal malignant melanoma, retinoblastoma, orbital sarcoma and lacrimal gland cancer) has been explained according to the UICC in a book edited by M. H. Harmer and J. A. Oosterhuis. Five studies concerning the difference in clinical results with and without a treatment were shown to confirm the meaning and importance of TNM classification of ophthalmic malignancies.


5. DOCID:25756 SCORE: 0.00273757188803295
DOCNO: 10452165
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Expression Regulation, Neoplastic
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: A M Rich AM
AUTHOR: D Kerdpon D
AUTHOR: P C Reade PC
AFFILIATION: Department of Stomatology, School of Dentistry, University of Otago, New Zealand.
PUBTYPE: Journal Article
JOURNALTITLE: Australian dental journal.
COUNTRY: AUSTRALIA
TITLE: p53 expression in oral precancer and cancer.
PUBDATE: 19990601
Expression of the p53 tumour suppressor gene is a frequent finding in human malignancies, including oral cancer, and it has been detected in some potentially malignant lesions. The results of the present project showed that 35 of the 41 (85 per cent) oral mucosal lesions with histological evidence of epithelial dysplasia expressed p53, but the presence or absence of p53 staining could not be used to predict the outcome of potentially malignant oral mucosal lesions.


6. DOCID:25462 SCORE: 0.00234332870415155
DOCNO: 11229082
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemically induced
QUALIFIER: drug effects
QUALIFIER: chemically induced
QUALIFIER: adverse effects
QUALIFIER: adverse effects
QUALIFIER: adverse effects
QUALIFIER: adverse effects
AUTHOR: C Magnusson C
AUTHOR: E Weiderpass E
AFFILIATION: Institutionen för medicinsk epidemiologi, Karolinska institutet, Stockholm. Cecilia.Magnusson@mep.ki.se
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Läkartidningen.
COUNTRY: Sweden
TITLE: [Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer]
PUBDATE: 20010101
Use of hormone replacement therapy alleviates menopausal symptoms effectively, prevents osteoporosis and may even reduce the risk of cardiovascular disease and dementia. However, little is known about the risk of breast cancer and endometrial cancer after long-term use of different estrogen-progestin combinations. A large epidemiological study in Sweden, in which combined estrogen-progestin treatment was predominantly used, is reported.


7. DOCID:26724 SCORE: 0.00226305834001248
DOCNO: 12450437
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: immunology
AUTHOR: S Kummar S
AUTHOR: T E Ciesielski TE
AFFILIATION: Department of Medicine, Yale Cancer Center, Yale University School of Medicine, VA Connecticut Cancer Center, VA Connecticut Healthcare System, West Haven, CT, USA. kummars@yahoo.com
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Clinical colorectal cancer.
COUNTRY: United States
TITLE: Cytokeratin staining for primary and metastatic colorectal cancer.
PUBDATE: 20011101
Determining the site of origin of metastatic adenocarcinoma lesions has obvious therapeutic and prognostic implications. Immunostaining for cytokeratin subtypes 7 and 20 is increasingly used to evaluate metastatic colorectal cancer lesions. We present the case of a patient with a history of colorectal cancer who subsequently developed an isolated metastatic lesion in the lung. As illustrated by our case, staining for cytokeratin subtypes can be helpful in determining the site of origin of metastatic lesions.


8. DOCID:25469 SCORE: 0.00225406689969552
DOCNO: 10921321
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Li-Fraumeni Syndrome
AUTHOR: Y Tsunematsu Y
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Li-Fraumeni syndrome]
PUBDATE: 20000701
Germ-line p53 point mutations have been reported for various families with Li-Fraumeni syndrome (LFS) characterized by a dominantly inherited increased susceptibility for the development of early age of onset neoplasms of diverse origin in multiple family members. Recently Bell et al reported that mutations in a known checkpoint gene called Chk2 cause some cases of LFS. This review will present the effective interaction of epidemiologic method and molecular genetics on the identification of cancer predisposition and will discuss about various problems of predictive testing for inherited mutations in cancer susceptibility genes.


9. DOCID:27472 SCORE: 0.00204387083676161
DOCNO: 10696841
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Diagnostic Imaging
DESCRIPTOR: Endoscopy, Gastrointestinal
QUALIFIER: diagnosis
QUALIFIER: diagnosis
AUTHOR: P Marteau P
AFFILIATION: Dept. of Gastroenterology, Laennec Hospital, Assistance Publique des Hôpitaux de Paris, and University of Paris V, France. philippe.marteau@lnc.ap-hop-paris.fr
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Endoscopy.
COUNTRY: GERMANY
TITLE: Inflammatory bowel disease.
PUBDATE: 20000201
This article reviews important papers on inflammatory bowel disease published between May 1998 and June 1999. It does not review every aspect of treatment, but focuses on the effects of anti-tumor necrosis factor antibodies on the inflammatory lesions. The new information summarized includes: the role of bacteria and the modulating effects of probiotics; the frequency of appendiceal orifice inflammation in ulcerative colitis; progress in imaging based on endoscopic ultrasonography, magnetic resonance imaging, and leukocyte scintigraphy; frequency and treatment of massive hemorrhage, viral superinfection, and persistent perineal sinus; and the pathogenesis, detection, and treatment of dysplasia and cancer.


10. DOCID:26689 SCORE: 0.00201559517708503
DOCNO: 10087759
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radionuclide imaging
QUALIFIER: radionuclide imaging
QUALIFIER: radionuclide imaging
AUTHOR: M Nakajo M
AFFILIATION: Department of Radiology, Faculty of Medicine, Kagoshima University.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Kaku igaku. The Japanese journal of nuclear medicine.
COUNTRY: JAPAN
TITLE: [Present status and progress of endocrine nuclear medicine]
PUBDATE: 19990101
The author reviewed present status and progress of endocrine nuclear medicine including thyroid, parathyroid, adrenocortical, adrenomedullary and somatostatin receptor imaging and also radionuclide therapy of Basedow's disease, metastatic foci of post-operative thyroid cancer and malignant neural crest tumor. Relatively new imaging agents include 99mTc-MIBI and 99mTc-tetrofosmin for parathyroid imaging and 111In-pentetreotide for somatostatin receptor imaging. It is hoped that therapy of malignant neural crest tumors such as metastatic pheochromocytoma and neuroblastoma with 131I-MIBG and somatostatin receptor imaging will be available in Japan as soon as possible.


11. DOCID:26150 SCORE: 0.00189191842410763
DOCNO: 10407696
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
QUALIFIER: methods
QUALIFIER: methods
AUTHOR: J J Erasmus JJ
AUTHOR: E F Patz EF
AFFILIATION: Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in pulmonary medicine.
COUNTRY: UNITED STATES
TITLE: Treatment of malignant pleural effusions.
PUBDATE: 19990701
Malignant pleural effusions are common in cancer patients with advanced disease. These patients usually present with chest pain, cough, and progressive shortness of breath, all of which may cause significant impairment in quality of life. Therapeutic options include systemic treatment; thoracentesis; or, most commonly, tube drainage and sclerotherapy. These procedures are usually palliative and are performed depending on patients' symptoms, underlying medical conditions, extent of disease, performance status, and prognosis. This review focuses on the diagnosis and treatment of patients with malignant pleural effusions.


12. DOCID:24699 SCORE: 0.00184959134181202
DOCNO: 9681592
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Perception
QUALIFIER: pathology
QUALIFIER: psychology
AUTHOR: B De Brabander B
AUTHOR: P Gerits P
AUTHOR: R Sacré R
AUTHOR: J Lamote J
AFFILIATION: Department of Research Methods and Behavioural Sciences, University of Antwerp, Belgium.
PUBTYPE: Journal Article
JOURNALTITLE: Psychiatry and clinical neurosciences.
COUNTRY: AUSTRALIA
TITLE: Can primary breast cancer patients sense the presence of lymph node metastasis? An unexpected research finding.
PUBDATE: 19980601
We found that primary breast cancer patients with lymph node metastasis, compared to patients without apparent metastasis, had a greater expectation that their breast lump biopsy would be malignant. This difference in expectation between the two groups remained after controlling for a range of possible confounding variables.


13. DOCID:25795 SCORE: 0.00184931830087485
DOCNO: 11525288
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: M J Putzi MJ
AUTHOR: A M De Marzo AM
AFFILIATION: Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Hematology/oncology clinics of North America.
COUNTRY: United States
TITLE: Prostate pathology: histologic and molecular perspectives.
PUBDATE: 20010601
The field of prostate cancer research is poised for dramatic improvements in our ability to better diagnose men at risk of prostate cancer and to better predict prognosis and response to treatment. Histopathologic and molecular analyses lie at the heart of these issues. Improvements in our understanding of the mechanisms of prostate carcinogenesis and in determining why the prostate seems to be so highly targeted for cancer development will lead to rational strategies of disease prevention.


14. DOCID:27591 SCORE: 0.00183823302153436
DOCNO: 10361559
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapy
AUTHOR: B A Tjoa BA
AUTHOR: A A Elgamal AA
AUTHOR: G P Murphy GP
AFFILIATION: Cancer Research Division, Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, Washington, USA.
PUBTYPE: Journal Article
JOURNALTITLE: The Urologic clinics of North America.
COUNTRY: UNITED STATES
TITLE: Vaccine therapy for prostate cancer.
PUBDATE: 19990501
Vaccine therapy may provide an alternative for prostate cancer patients whose disease no longer responds to hormone therapy. Administration of dendritic cells pulsed with prostate-specific membrane antigen (PSMA) induces cellular immune responses against the tumor with virtually no adverse effects. About 30% of the evaluable patients were identified as partial responders, based on the National Prostate Cancer Project (NPCP) criteria. In addition, there was a 50% decrease of serum prostate-specific antigen or resolution of previously measurable lesions on imaging. Dendritic cell vaccine therapy may have a synergistic effect, when combined with other therapies.